Q1 EPS Estimates for Avalo Therapeutics Lifted by Wedbush

Avalo Therapeutics, Inc. (NASDAQ:AVTX) – Wedbush increased their Q1 2025 earnings per share estimates for Avalo Therapeutics in a research report issued on Thursday, March 20th. Wedbush analyst R. Driscoll now expects that the company will post earnings per share of $0.63 for the quarter, up from their prior estimate of $0.55. Wedbush has a “Outperform” rating and a $18.00 price objective on the stock. The consensus estimate for Avalo Therapeutics’ current full-year earnings is ($19.07) per share.

Other equities research analysts also recently issued research reports about the stock. BTIG Research began coverage on shares of Avalo Therapeutics in a report on Thursday, December 19th. They issued a “buy” rating and a $40.00 price objective for the company. Piper Sandler began coverage on Avalo Therapeutics in a report on Friday, February 28th. They issued an “overweight” rating and a $48.00 target price on the stock. Finally, HC Wainwright reiterated a “neutral” rating on shares of Avalo Therapeutics in a research report on Thursday. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $35.33.

Avalo Therapeutics Price Performance

Avalo Therapeutics stock opened at $8.22 on Friday. The firm has a 50-day moving average price of $7.44 and a two-hundred day moving average price of $9.11. Avalo Therapeutics has a 52-week low of $4.43 and a 52-week high of $34.46.

Institutional Investors Weigh In On Avalo Therapeutics

Several hedge funds have recently bought and sold shares of AVTX. BVF Inc. IL lifted its position in shares of Avalo Therapeutics by 7.2% in the fourth quarter. BVF Inc. IL now owns 1,036,679 shares of the company’s stock worth $7,703,000 after purchasing an additional 69,679 shares in the last quarter. Ikarian Capital LLC grew its holdings in shares of Avalo Therapeutics by 1,673.0% during the 3rd quarter. Ikarian Capital LLC now owns 970,359 shares of the company’s stock valued at $9,218,000 after acquiring an additional 915,629 shares in the last quarter. RA Capital Management L.P. purchased a new stake in shares of Avalo Therapeutics during the third quarter worth $9,186,000. Affinity Asset Advisors LLC grew its stake in Avalo Therapeutics by 1,123.9% in the fourth quarter. Affinity Asset Advisors LLC now owns 550,765 shares of the company’s stock valued at $4,092,000 after purchasing an additional 505,765 shares in the last quarter. Finally, Velan Capital Investment Management LP acquired a new position in Avalo Therapeutics in the 4th quarter worth about $817,000. 87.06% of the stock is owned by hedge funds and other institutional investors.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.